National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Bedaquiline (Sirturo®)

Bedaquiline (Sirturo®) is indicated for use as part of an appropriate combination regimen for pulmonary MDR‑TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Rapid Review

Commenced Completed Outcome
23/01/2015 20/02/2015 Full Pharmacoeconomic Evaluation Not Recommended


Full HTA not required.  The NCPE however recommend that if reimbursed that use of bedaquiline be subject to certain conditions.